|
Effect of
Life Style Modification with or Without Metformin on Monocyte
Chemoattractant Protein-1(MCP-1) Levels in Premenopausal Women with
Metabolic Syndrome
Eman H.EL-Adawy(1), Amany A. Moussa(1),
Mervat M. Eleshmawi(1), Amal Seleem(2) &
Mohammed H. Daba(3)
Departments of Internal Medicine(1), Medical Biochemistry(2)
& Pharmacology(3), Faculty of Medicine, Mansoura
University, Egypt
Tanta Med. Sc. J 2009; 4(3):105-112
ICID: 907315
Article type: Original articleIC™ Value: 4.54
| Abstract provided by Publisher |
 |
Background/Aim: MCP-1 is an inflammatory marker which can be
considered one of the adipokines. MCP-1 has been studied in patients
with obesity and insulin resistance with variable results. Insulin
resistance and inflammation has been linked to metabolic syndrome.
Our objective was to investigate the MCP-1 level in obese women with
metabolic syndrome and study the effect of different strategies
which modulates insulin resistance such as life style modification
versus metformin on MCP-1 level. Patients &Methods: Body mass index
(BMI), waist circumference (WC), blood pressure (BP), fasting blood
glucose (FBG), lipid profile, Homeostasis model assessment of
insulin resistance (HOMA-IR), plasma MCP-1, and C- reactive protein
(CRP) were assessed in 40 obese premenopausal women. Subjects
fulfilling the criteria of metabolic syndrome (20 women) were
reassessed after 12 weeks of diet/exercise alone (10 women) versus
diet/exercise in addition to2000 mg/day metformin (10 women).
Results: Generally, plasma MCP-1 was significantly elevated in obese
women compared with normal control and showed significant elevation
in those with metabolic syndrome compared to obese without metabolic
syndrome, MCP-1levels were significantly higher in patients with
high waist circumference, insulin resistance (HOMA-IR) and high CRP
. After 12 weeks of intervention, MCP-1 decreased in both groups
,but significantly lower in metformin-treated group (178.1±12.8
vs.128.5±4.5ng/ml) than diet/exercise alone group, (183.6±10.7ng/ml
vs. 162.9±7.8ng/ml) and showed significant correlation with WC,
HOMA-IR and CRP. Conclusion: Plasma MCP-1 concentration is elevated
in obese women with metabolic syndrome and correlated with BMI,
insulin resistance and CRP. Plasma MCP-1 concentration is suppressed
with metformin treatment more than life style modification alone,
suggestive of the possible role of MCP-1 in insulin resistance and
inflammatory state seen in obesity with metabolic syndrome and the
possible anti-inflammatory effect of metformin in the management of
metabolic syndrome beyond improving insulin resistance.
ICID 907315
|